8:00 am Registration & Networking

8:40 am Chairs’ Opening Remarks

8:45 am Characterization & Use of Microphysiological Systems (MPS) in Pharmaceutical Safety & ADME Applications

  • Terry Van Vleet Head of Investigative Toxicology, Pathology, Molecular & Computational Toxicology, Abbvie

9:15 am An NCATS Perspective: Progress & Future Applications of Organ-on- Chip Systems

9:45 am Physiologically Relevant 3D hiPSC-Based Platforms Empowering Drug Discovery

10:15 am Speed Networking & Morning Networking Break

11:00 am PANEL DISCUSSION: The Future of 3D Tissue Model Adoption

11:45 am Microfabricated Organ-on-Chip Models: High-Throughput Flow, Culture, & Data Collection

12:15 pm Networking Lunch

Drug Discovery & Developmental Progress of 3D Tissue Models in General Disease Applications

1:45 pm  Progress in Applying Microphysiological Systems for Drug Safety Assessment

Rhiannon David
Microphysiological Systems Scientific Lead, AstraZeneca

2:15 pm TissueSpec® Bone, Liver, and Lung ECM substrates as a metastasis research platform to predict drug efficacy

Evelyn Aranda
Senior Research Scientist, XYLYX Bio

2:45 pm Developing Translationally Relevant 3D Models for Pre-Clinical Drug Development

Jason Ekert
Senior Director & Head of Complex In Vitro Models, GlaxoSmithKline

3:15 pm Fat-on-Chip for Drug Discovery & Preclinical Studies

Travia Frazier
President & CEO, Obatala Sciences

3:30 pm 3D Bioprinted Vascularized Glioblastoma Model

Guohao Dai
Associate Professor - Biomedical Engineering, Northeastern University

4:00 pm A Simple High-Throughput Approach Identifies Actionable Drug Sensitivities in Patient-Derived Tumor Organoids.

Alice Soragni
Assistant Professor & Principal Investigator, UCLA

1:45 pm 3D Cell Models for Comprehensive Drug Metabolism & Pharmacokinetics Assessment

Jinping Gan
Senior Principal Scientist, Bristol-Myers Squibb

2:15 pm Closing the Human Translation Gap for Cardiac Risk Assessment

Misti Ushio
CEO, Tara Biosystems

2:45 pm Advancements in Human Liver Platforms for ADME Studies

Niresh Hariparsad
Director - Drug Metabolism & Pharmacokinetics Project Leader, Vertex Pharmaceuticals

3:15 pm Engineered 3D Heart Tissues as Models of Disease and Discovery

Nicholas A. Geisse,
Chief Scientific Officer, NanoSurface Biomedical Inc.

3:30 pm Advanced In Vitro Assays for De-Risking Cardiac Liabilities Associated with Small Molecule Candidates

Piyush Bajaj
Principal Scientist, Sanofi

4:00 pm Assessment of Donor-to-Donor Variability in Human Gut Organoids

Linda Lieberman
Principal Scientist, Merck & Co

4:30 pm Afternoon Networking & Dedicated Poster Session

5:00 pm Liver MPS Systems for Safety Assessment

5:30 pm Human Intestinal Organoids to Study the Gut Endocrine Cells

6:00 pm Close of Conference Day 1